CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 9ab2e887-2e5b-429a-8d89-fd6d7813a028
exploratory
What does the current evidence establish about Ace Inhibitors Aging and human geroscience? This synthesis tests the thesis that evidence for ACE inhibitors aging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed for hypertension, yet whether they confer direct anti-aging benefits—attenuating frailty, preserving muscle function, or extending lifespan beyond blood-pressure control—remains debated. This synthesis applied a structured, AI-assisted evidence-synthesis approach with an auditable trail to integrate 47 curated reference papers spanning randomized trials, observational cohorts, and preclinical mechanistic studies on ACE inhibitors and aging-related outcomes. Functional aging endpoints were similarly ambiguous: ACE inhibitor therapy did not improve gait-speed reserve beyond statin effects in older adults (Spiegeleer 2025), and in the LACE trial ACE I/D genotype associated with grip and quadriceps strength in sarcopenic men but ACE inhibitor treatment itself did not produce a significant strength response (Rossios 2023). Importantly, no direct human trial with aging-specific primary endpoints—such as frailty incidence, sarcopenia progression, or all-cause longevity in non-diseased older adults—was identified in this synthesis. The mechanistic plausibility that ACE inhibition modulates inflammation, e
Contradiction: none
Sources: 5
exploratoryThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.
Contradiction: none
Sources: 5
exploratoryPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.
Contradiction: none
Sources: 5
exploratoryEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.
Contradiction: none
Sources: 5
exploratorySource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.
Contradiction: none
Sources: 5
exploratoryOutcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.
Contradiction: none
Sources: 5
exploratory| Contextual Adjacent Evidence | n=26; claims=1346 | null signal in 17/26 sources | 1 direct; 21 indirect; 1 mechanistic; 3 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Cardiometabolic | n=5; claims=634 | null signal in 2/5 sources | 1 direct; 3 indirect; 1 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Safety and Comorbidity | n=4; claims=145 | null signal in 3/4 sources | 3 indirect; 1 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Immune | n=2; claims=197 | null signal in 2/2 sources | 1 indirect; 1 mechanistic | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Muscle Function | n=1; claims=49 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
Contradiction: none
Sources: 5
exploratoryThe evidence base for ACE inhibitors in the context of aging-related cardiometabolic outcomes comprises five studies, predominantly observational in design. Lin 2026 conducted an observational cohort emulating a target trial, examining mean weight change associated with initiation of and adherence to antihypertensive medications, including lisinopril, relative to comparators like amlodipine over a 24-month period in adults. Din 2026 performed a prospective randomized controlled study evaluating sexual function among hypertensive females receiving ramipril 2.5 mg daily for one month. Spiegeleer 2025 focused on older adults in an observational cohort, analyzing the association between statins and gait speed reserve (GSR) while considering concomitant medications, including ACE inhibitors. Azizzadeh 2026 conducted an observational cohort study, the LEAD study, examining the prevalence and determinants of vascular aging in Austrian adults, which included pharmacological treatments for diabetes and hypertension. The single clinical RCT, Zhang 2025, compared nifedipine-GITS and ramipril in Chinese and European patients with hypertension, providing direct evidence on blood pressure reduction.
Contradiction: none
Sources: 5
exploratoryQuantitative findings across these studies present a mixed profile, with no consistent cardiometabolic benefit or harm linked specifically to ACE inhibitors in aging contexts. Din 2026 reported a mixture of significant (P < 0.05, P < 0.05) and non-significant (P > 0.05) findings across different functional and cardiometabolic endpoints. The clinical RCT by Zhang 2025 demonstrated that both nifedipine-GITS and ramipril similarly reduced blood pressure, reporting a P = 0.02 for a comparative endpoint. By contrast, Azizzadeh 2026 reported no p-values in the provided excerpts, indicating a null or unreported effect for ACE inhibitor use on vascular aging determinants.
Contradiction: none
Sources: 5
exploratoryMechanistically, the rationale for ACE inhibitors influencing aging-related cardiometabolic pathways centers on modulation of the renin-angiotensin system, which can affect vascular health, insulin sensitivity, and adiposity. Preclinical data and theoretical frameworks suggest potential benefits on endothelial function and oxidative stress. However, the human evidence from this corpus does not provide clear support. The clinical RCT by Zhang 2025 supports efficacy for blood pressure control, a key cardiometabolic risk factor, but its design does not assess aging-specific endpoints. Observational studies like Azizzadeh 2026, which explicitly examine vascular aging, report null findings, suggesting that in real-world populations, the benefit of ACE inhibitors may not extend beyond hypertension management to modify core aging trajectories.
Contradiction: none
Sources: 5
exploratoryWithin the corpus, tensions are evident. Azizzadeh 2026, reporting null findings on vascular aging determinants, stands in disagreement with Spiegeleer 2025, which found mixed and significant associations between concomitant medications (potentially including ACE inhibitors) and gait speed reserve in older adults. Similarly, the null findings reported in Din 2026 for certain functional outcomes contrast with the unclear or negative signals reported in Lin 2026 and Zhang 2025, respectively, regarding weight change and blood pressure outcomes. The primary tension, therefore, is between studies suggesting potential functional or vascular impacts and those reporting no independent association with aging metrics, underscoring that the current evidence does not establish ACE inhibitors as standalone geroprotective agents for cardiometabolic health.
Contradiction: none
Sources: 5
exploratoryThe SAFE trial, a randomized, phase 3, double-blind, placebo-controlled trial, provided the most direct human RCT evidence within the corpus. This 2x2 factorial design evaluated the cardioprotective effects of ramipril, bisoprolol, or their combination in breast cancer patients receiving anthracycline chemotherapy.
Contradiction: none
Sources: 5
exploratoryObservational data from a cohort study following transcatheter aortic valve implantation (TAVI) provided more mixed evidence. The RASTAVI trial, a prospective randomized open, blinded endpoint (PROBE) design, compared ramipril with standard care in patients without reduced ejection fraction.
Contradiction: none
Sources: 5
exploratoryThe evidence base reveals notable tensions regarding context-dependency. By contrast, the positive cardioprotective signal from the anthracycline-exposed SAFE cohort (Meattini 2025; Bene 2025) stands in disagreement with the null or mixed findings from the TAVI (AmatSantos 2024) and post-myocardial infarction (Wang 2023) populations. These disagreements suggest that any potential geroprotective or cardioprotective benefit of ACE inhibitors is highly specific to the clinical context and underlying pathophysiology, rather than a generalizable effect.
Contradiction: none
Sources: 5
exploratoryMechanistically, the substrate for these cognitive findings may involve ACE inhibitor effects on cerebral microvascular function and endothelial health, processes that deteriorate with vascular aging. This theoretical basis is further supported by a systematic review linking methylarginine levels, modulators of nitric oxide synthesis, to vascular aging, although direct evidence for ACE inhibitor modulation of this pathway in humans remains sparse (Carmo 2025).
Contradiction: none
Sources: 5
exploratoryWithin this outcome class, a significant tension exists between the null primary cognitive findings in the MCI trial (Hajjar 2020) and the positive cerebrovascular reactivity finding from the CEDAR study (Henley 2023). This disagreement highlights a disconnect between a potential mechanistic effect on cerebral perfusion and a lack of demonstrable benefit on standardized cognitive batteries. Furthermore, the severity of the disagreement is amplified when considering that the positive CEDAR finding contrasts with numerous null effects on other vascular aging markers across the corpus, suggesting that any cerebrovascular benefit may be narrow and not broadly anti-aging.
Contradiction: none
Sources: 5
exploratoryMechanistically, the renal protective effects observed in cardiac surgery may be mediated through modulation of intra-renal hemodynamics and reduction of inflammation, pathways relevant to age-related nephron loss (Kilic 2026). The high attrition rate observed in the Singapore cohort (Senanayake 2026) points to a mechanistic tension between the theoretical long-term benefits of ACE inhibition and the practical reality of patient tolerance and persistence. Furthermore, the case of lisinopril-induced hallucinations (Golder 2026) suggests a potential, if rare, effect on central neurotransmitter systems, a consideration for geriatric prescribing.
Contradiction: none
Sources: 5
exploratoryA notable tension emerges between the positive renal protection signal from a surgical context (Kilic 2026) and the broader pattern of null or mixed findings for ACE inhibitors in other aging-related domains across the corpus. The pragmatic finding of high treatment discontinuation (Senanayake 2026) stands in disagreement with any assumption of straightforward long-term geroprotective use. Collectively, these systemic and safety outcomes reinforce that the risk-benefit profile of ACE inhibitors in older adults is complex, with specific benefits in certain procedural contexts coexisting with practical adherence barriers and potential adverse effects.
Contradiction: none
Sources: 5
exploratoryThe evidence for ACE inhibitor effects on frailty is derived exclusively from a preclinical model. Translational relevance to humans remains uncertain. The intervention involved a dose of 30 mg/kg/day administered via feed. The primary outcome assessed was the attenuation of frailty development in middle-aged animals.
Contradiction: none
Sources: 5
exploratoryPreclinical data from Keller 2019 suggest that enalapril treatment attenuated the development of frailty in aging mice. The study also reported differential modification of pro- and anti-inflammatory cytokines between male and female animals. However, no p-values or effect sizes were provided in the available excerpts to quantify these changes. The effect direction for the overall frailty outcome was classified as unclear due to the limited mechanistic focus.
Contradiction: none
Sources: 5
exploratoryMechanistically, the attenuation of frailty in the mouse model is proposed to involve modulation of the renin-angiotensin system and associated inflammatory pathways. Keller 2019 specifically noted differential cytokine responses, suggesting a biological basis for the observed functional changes. This provides theoretical plausibility for a role of ACE inhibitors in age-related frailty, but the pathway has not been validated in human clinical populations.
Contradiction: none
Sources: 5
exploratoryA fundamental tension exists within this evidence base: the sole available study is a preclinical investigation in mice, and no direct human trials with aging-specific endpoints such as frailty were identified in the corpus. While mechanistic plausibility is suggested by the animal data, this does not equate to proven clinical benefit in humans. The translation from rodent models to human geriatric outcomes remains an unresolved challenge.
Contradiction: none
Sources: 5
exploratoryThe evidence base for ACE inhibitor effects on immune outcomes is derived from two distinct study types with no direct human trials on aging-specific endpoints. An observational cohort study by Shen and colleagues examined the association between food allergen sensitization and early vascular aging (EVA) in adults. This study identified that sensitization to at least one common food allergen was associated with an increased risk of EVA, with an odds ratio (OR) of 1.91 (95% confidence interval [CI], 1.1 to 3.3). The population studied were adults, and the study did not directly assess ACE inhibitor use, providing only contextual, indirect evidence.
Contradiction: none
Sources: 5
exploratoryPreclinical data provide the primary mechanistic foundation for investigating immune modulation. A study in spontaneously hypertensive rats (SHR) by Diego and colleagues evaluated the modulation of pro-inflammatory cytokines by nebivolol-based polytherapies with valsartan or lisinopril. Translational relevance to humans remains uncertain. These preclinical results suggest a mechanistic basis for ACE inhibitors influencing inflammatory pathways relevant to aging, though this effect was observed in a polypharmacy context in hypertensive animals.
Contradiction: none
Sources: 5
exploratoryWithin the curated corpus, there is a tension in the directness of evidence. The preclinical study by Diego 2024 offers strong mechanistic data on cytokine modulation, while the observational study by Shen 2025 provides only indirect, contextual evidence linking immune factors to vascular aging. Both studies report null or context-dependent overall findings regarding ACE inhibitors as standalone agents for immune aging outcomes. This divergence underscores the current incomplete state of the evidence, where mechanistic plausibility coexists with a lack of direct human trial data on aging-specific immune endpoints.
Contradiction: none
Sources: 5
exploratoryThe sole identified study investigating ACE inhibitor effects on immune and inflammatory pathways in the context of viral infection was an observational cohort using a transgenic mouse model. Animals were treated with lisinopril at a dose of 10 mg/kg per day for 21 days prior to intranasal inoculation with 10⁵ PFU of SARS-CoV-2 (Wuhan strain). The experimental design assessed viral load, ACE2 receptor expression in lung tissue, and markers of inflammatory response following infection. This preclinical model is relevant to the aging context because ACE2 expression changes with age and because the RAS axis is implicated in inflammaging. However, it is important to note that no direct human trials with aging-specific endpoints such as frailty, muscle function, or longevity were identified in the corpus. The study thus provides only indirect, mechanistic evidence regarding immune and inflammatory modulation by ACE inhibitors.
Contradiction: none
Sources: 5